With the rapid adoption of technology, digital solutions and new modalities in the wake of COVID-19, cancer patients and extended care teams have a plethora of resources geared towards improving access, reducing financial toxicity and easing the burden of navigation. And yet, many remain lost within the labyrinth of information overload. This article highlights the increasing need to go beyond HUB services and a convener approach, and instead look to root causes with the patient at the center.
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Very interesting study which gives more support for preoperatory therapy in the setting of borderline resectable pancreatic cancer. The use of neodjuvant chemotherapy or chemoradiotherapy will likely increase overtime, as systemic options improve, even in pancreatic cancer. Optimal regimen is unknown as studies with other options such as Folfirinox, gemcitabine/albumin-bound paclitaxel are needed, post chemoradiotherapy.
The importance of germline mutation assessment with the support of genetic counselors cannot be overestimated in daily practice. The impact can be very significant. Interesting to see the significantly elevated relative risk for GI cancers (pancreas, gastric) with BRCA 1 and 2 pathogenic variants.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Unfortunately, another negative study of a drug being accretive to CHOP regimen in T-cell NHL. Newer drugs and concepts hopefully will move the needle in this decade.
Interesting and encouraging development in this setting. The science and applicability of this drug in the scenario of no/low HER-2 expression will be thought-provoking. Interstitial pneumonitis is a concern.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
The difference in CR vs RD rates with addition of carboplatin or bevacizumab was quite impressive. It is likely that the study was simply not powered to measure other endpoints. While LTOs were not improved, pCR was associated with superior LTOs. Biological markers of response are very interesting and may help us tailor specific therapies in the future.
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
Many of us have used platinum/paclitaxel in this setting but this study helps to corroborate the clinical practice.
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Benefit of locoregional control seems limited probably to situations in which surgery could clearly help recurrent breast inflammatory/infectious issues. This study is helpful to quote to patients who are anxious about not having breast surgery accomplished in this setting.
A single-group, phase 1–2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.
Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors
More evidence that being physically active may enhance QOL and survival. Prospective studies are needed to show that physical activity intervention actually achieves such degree of improvements, and that the non-exercise population is not self-selected due to comorbidities.